Puma biotechnology, inc. (PBYI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12Sep'12Jun'12Mar'12Dec'10
Operating activities:
Net loss

-16,933

-11,199

-16,885

-37,424

-10,087

-30,695

-14,201

-44,334

-24,345

-64,078

-77,180

-77,832

-72,865

-72,661

-65,781

-66,597

-70,972

-61,719

-60,417

-64,694

-52,454

-47,483

-35,844

-38,844

-19,794

-21,912

-25,859

-14,754

-11,826

-7

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,916

1,899

1,943

2,100

2,135

2,105

2,055

1,883

1,341

1,360

900

274

277

584

110

247

208

208

199

189

180

189

159

146

133

77

68

69

48

0

Built-out allowance received from landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

179

-

-

-

-

-227

0

0

-236

0

Stock-based compensation

8,907

11,536

12,213

15,440

18,138

18,596

20,807

22,184

25,352

25,522

26,491

26,958

29,764

29,274

29,751

28,729

29,510

21,680

24,957

28,194

20,103

16,372

10,449

7,167

5,163

587

358

263

198

0

Disposal of property and equipment

-

0

0

-53

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Anti-dilutive warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,972

6,464

-65

-149

0

Changes in operating assets and liabilities:
Accounts receivable, net

2,646

1,714

1,836

-55,638

60,211

1,023

-1,593

5,034

6,639

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory, net

127

47

-137

623

12

-207

357

-267

713

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-11,536

3,483

-

-

-

-

0

Prepaid expenses and other

1,140

2,337

-647

-1,028

-1,230

1,084

461

-1,750

1,045

1,854

1,166

-1,362

-516

-581

-1,961

-1,041

170

252

806

31

-131

2,991

497

4,951

145

218

-226

458

256

0

Other current assets

-18

1

-8

-9,825

8,368

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-1,928

10,102

-6,015

-13,807

8,194

4,380

-5,882

-1,289

-4,217

10,153

-6,975

544

3,935

-844

-3,746

-213

7,034

8,020

-661

-2,164

-2,389

-3,451

-349

3,605

4,500

-

-

-

-

0

Accrued expenses

434

-7,741

2,520

3,970

23,850

4,914

326

6,633

3,910

1,040

7,034

2,814

2,334

705

2,377

276

-571

-909

-107

2,186

-15,975

18,533

1,776

4,084

-3,528

-

-

-

-

0

Deferred rent

41

-

-

-

-

61

-353

-14

-103

32

32

32

3

-221

-437

-3,521

67

59

32

-13

-202

-178

16

116

-107

-344

-21

112

67

0

Post-marketing commitment liability

-

0

0

0

9,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-11,500

1,600

-7,300

44,230

-16,130

7,047

-7,262

-17,637

-6,253

-35,609

-54,907

-45,912

-36,042

-40,961

-34,891

-30,810

-35,028

-33,031

-36,867

-34,547

-50,023

-18,461

-24,322

-17,373

-17,047

-24,809

-7,644

-8,774

-2,784

-7

Investing activities:
Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,118

6,058

8,896

-

Purchase of property and equipment

-

-

-

-

-

-111

305

205

40

145

154

8

124

557

65

3,621

44

59

152

356

435

546

128

212

214

153

9

240

187

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

1

-

-

-

-

-

-

-

-

0

1

156

0

0

Expenditures for leasehold improvements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

179

82

0

106

4

234

0

0

236

0

Purchase of available-for-sale securities

-

126

-902

41,259

86,715

-

-

-

-

1

215

-215

79,728

0

19,067

25,959

36,768

3,023

25,063

81,882

104,838

-

-

-

-

-

-

-

-

-

Maturity of available-for-sale securities

34,377

0

9,935

52,465

42,132

-

-

-

-

26,628

44,446

17,871

25,779

21,393

48,600

43,005

118,269

42,765

23,566

14,122

52,769

22,831

4,098

35,187

8,161

-

-

-

-

-

Net cash provided by (used in) investing activities

34,377

-432

38,972

11,206

-44,583

2,582

-21,360

-38,805

-40

-23,518

44,076

18,079

-54,073

20,839

29,467

10,427

81,456

39,682

-4,746

-68,116

-52,683

22,204

-2,771

-90,651

7,943

-388

-11

-396

-424

0

Financing activities:
Proceeds from issuance of stockholder's convertible note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-63

205,196

0

0

0

129,440

-

-

-

-

0

Net proceeds from shares issued under employee stock plans

-

-1

76

194

1,082

501

1,010

2,994

3,147

12,683

9,731

3,565

706

225

129

0

222

1,320

5,374

7,097

14,437

-

-

-

-

-

-

-

-

0

Capital contributions by stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

Net cash provided by financing activities

-

-1

76

-68,224

1,082

30,492

1,010

73,802

3,147

61,108

9,731

3,565

706

162,079

129

0

222

1,320

5,374

7,034

219,633

6,533

0

0

129,440

-

-

-

-

7

Net increase (decrease) in cash, cash equivalents and restricted cash

22,837

1,133

31,741

-12,771

-59,631

40,121

-27,612

17,360

-3,146

1,981

-1,100

-24,268

-89,409

141,957

-5,295

-20,383

46,650

7,971

-36,239

-95,629

116,927

10,276

-27,093

-108,024

120,336

104,061

-7,655

-9,171

-3,208

0

Supplemental disclosures of non-cash investing and financing activities:
Property and equipment purchases in accounts payable

13

-

-

-

-

-

-91

65

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables related to stock option exercises

-

-

-

-

11

-

-

91

68

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information:
Interest paid

2,275

2,275

1,550

4,686

3,228

2,921

2,689

1,456

989

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-